使用醋酸氢化可的松对犬过敏性外耳炎进行主动治疗：一项回顾性观察研究
Proactive Treatment of Canine Allergic Otitis Externa With Hydrocortisone Aceponate: A Retrospective Observational Study.
文献信息
| PMID | 42904785 |
|---|---|
| 原文 | 在 PubMed 查看原文 ↗ |
| 发表日期 | 2026 |
| 作者 | Elisa Maina |
| 作者单位 | Division of Clinical Dermatology, Department of Clinical Veterinary Medicine, Vetsuisse Faculty, University of Bern, Bern, Switzerland. |
| 期刊 | Veterinary medicine and science |
| SCI 分区 | Q2 |
| IF | 2.4 |
| 研究类型 | 临床研究 · 临床 |
| 所属专科 | 耳科 |
中文摘要
背景： 过敏性外耳炎在犬中常见，复发可能导致反复就诊和抗菌药物使用。关于长期主动局部糖皮质激素维持治疗的数据有限。
目的： 描述接受主动醋酸氢化可的松维持治疗的过敏性外耳炎犬12个月内的复发频率，并比较连续日与非连续日给药方案。
方法： 回顾性审查了被开具醋酸氢化可的松耳喷剂的客户拥有犬的医疗记录。维持治疗在临床和细胞学缓解后开始。仅纳入确认继续治疗、合并过敏管理稳定且具有完整12个月结局数据的犬。复发定义为需要兽医检查、细胞学检查和额外耳部治疗的复发性外耳炎。犬按方案分组：方案1，每周连续两天；方案2，每周非连续两天。使用Fisher精确检验和Mann-Whitney U检验比较结局。
结果： 共纳入71只犬；方案1有36只，方案2有35只。在12个月内，50/71只犬（70.4%）无复发，12/71只（16.9%）复发一次，9/71只（12.7%）多次复发。方案1中至少一次复发发生于9/36只犬（25.0%），方案2中为12/35只（34.3%）（p = 0.443）。多次复发分别发生于2/36只（5.6%）和7/35只（20.0%）犬（p = 0.085）。两种方案之间的复发次数无显著差异（p = 0.290）。
结论： 大多数犬在主动醋酸氢化可的松维持治疗期间无复发或仅复发一次。未检测到两种方案之间的统计学显著差异，但不能得出等效性或非劣效性结论。
英文摘要
BACKGROUND: Allergic otitis externa is common in dogs and recurrence may lead to repeated consultations and antimicrobial use. Long-term data on proactive topical corticosteroid maintenance are limited.
OBJECTIVES: To describe 12-month relapse frequency in dogs with allergic otitis externa receiving proactive hydrocortisone aceponate maintenance therapy and compare consecutive-day and non-consecutive-day schedules.
METHODS: Medical records of client-owned dogs prescribed hydrocortisone aceponate ear spray were retrospectively reviewed. Maintenance started after clinical and cytological remission. Only dogs with confirmed continuation, stable concomitant allergy management and complete 12-month outcome data were included. Relapse was defined as recurrent otitis externa requiring veterinary examination, cytology and additional otic treatment. Dogs were grouped by schedule: Protocol 1, two consecutive days; and Protocol 2, two non-consecutive days weekly. Outcomes were compared using Fisher exact and Mann-Whitney U tests.
RESULTS: Seventy-one dogs were included; 36 in Protocol 1 and 35 received Protocol 2. During 12 months, 50/71 dogs (70.4%) had no relapse, 12/71 (16.9%) had one relapse and 9/71 (12.7%) had multiple relapses. At least one relapse occurred in 9/36 dogs (25.0%) in Protocol 1 and 12/35 (34.3%) receiving Protocol 2 (p = 0.443). Multiple relapses occurred in 2/36 (5.6%) and 7/35 (20.0%) dogs, respectively (p = 0.085). Relapse counts did not differ significantly between protocols (p = 0.290).
CONCLUSIONS: Most dogs had no relapse or only one relapse during proactive hydrocortisone aceponate maintenance. No statistically significant difference was detected between schedules, but equivalence or non-inferiority cannot be concluded.